Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial
Benjamin Besse1, Jessica J Lin2, Lyudmila Bazhenova3
1Paris-Saclay University, Gustave Roussy Cancer Center, Villejuif, France. Benjamin.BESSE@gustaveroussy.fr.
Abstract:
Early-generation TRK tyrosine kinase inhibitors (TKIs) approved for treating NTRK fusion-positive (NTRK+) solid tumors provide clinical benefit; however, resistance emerges. Repotrectinib is a next-generation ROS1/TRK TKI with a compact macrocyclic structure designed to improve durability of response. TRIDENT-1 is a registrational phase 1/2 trial assessing repotrectinib, a next-generation ROS1/TRK TKI, in adults with advanced solid tumors, including NTRK+ disease. The primary endpoint was confirmed objective response; secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival and safety. Median follow-up ranged between 21.3 months and 25.7 months. In the TKI-naive cohort (n = 51; 95% confidence interval (CI)), the response rate was 59% (44-72); the median DOR was not estimable (NE); and the median PFS was 30.3 months (9.0-NE). In the TKI-pretreated cohort (n = 69; 95% CI), the response rate was 48% (36-60); the median DOR was 9.8 months (7.4-13.0); and the median PFS was 7.4 months (3.9-9.7). Of 30 TKI-pretreated patients with NTRK solvent front mutations, 16 had a response (53%; 95% CI: 34-72). Intracranial responses were observed in two of three TKI-naive patients and in four of six TKI-pretreated patients with measurable intracranial disease at baseline. Among all treated patients (n = 565), the most common any-grade treatment-related adverse event (TRAE) was dizziness (57%); most TRAEs were low grade; and 4% discontinued repotrectinib due to a TRAE. Here repotrectinib demonstrated durable systemic and intracranial responses with generally low-grade adverse events in patients with NTRK+ solid tumors, including those with previous TRK TKI treatment and solvent front mutations. These results support the use of repotrectinib to treat patients with NTRK+ solid tumors. ClinicalTrials.gov identifier: NCT03093116 .
Insights
Repotrectinib, a next-generation tyrosine kinase inhibitor (TKI), shows durable responses in NTRK fusion-positive solid tumors. This TKI is effective even in patients previously treated with TKIs and those with specific mutations, demonstrating a favorable safety profile.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Early-generation TRK tyrosine kinase inhibitors (TKIs) offer clinical benefits for NTRK fusion-positive (NTRK+) solid tumors but are limited by emerging resistance.
- Repotrectinib is a next-generation ROS1/TRK TKI engineered with a macrocyclic structure to enhance response durability.
Purpose of the Study:
- To assess the efficacy and safety of repotrectinib in adult patients with advanced solid tumors, specifically focusing on NTRK+ disease.
- To evaluate repotrectinib's performance in both TKI-naive and TKI-pretreated patient populations, including those with specific NTRK solvent front mutations.
Main Methods:
- The TRIDENT-1 trial (Phase 1/2, NCT03093116) evaluated repotrectinib in patients with advanced solid tumors, including NTRK+ disease.
- Primary endpoint: confirmed objective response rate. Secondary endpoints: duration of response (DOR), progression-free survival (PFS), overall survival, and safety.
- Patients were stratified into TKI-naive and TKI-pretreated cohorts, with subgroup analyses for solvent front mutations and intracranial disease.
Main Results:
- In TKI-naive patients (n=51), response rate was 59% (95% CI: 44-72) with a median PFS of 30.3 months (9.0-NE).
- In TKI-pretreated patients (n=69), response rate was 48% (95% CI: 36-60) with a median DOR of 9.8 months (7.4-13.0) and median PFS of 7.4 months (3.9-9.7).
- Of 30 TKI-pretreated patients with NTRK solvent front mutations, 16 responded (53%; 95% CI: 34-72). Intracranial responses were observed in both cohorts.
Conclusions:
- Repotrectinib demonstrated durable systemic and intracranial responses in patients with NTRK+ solid tumors, including those with prior TRK TKI treatment and solvent front mutations.
- The treatment-related adverse events were generally low-grade, with a low discontinuation rate (4%), supporting repotrectinib's favorable safety profile.
- These findings support repotrectinib as a valuable therapeutic option for patients diagnosed with NTRK fusion-positive solid tumors.
Related Concept Videos
Phase Diagrams
Phase Transitions: Melting and Freezing
Predicting Products: SN1 vs. SN2
With increased substitution on the alkyl halide,...
Nuclear Fusion
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
Structures of Solids
Phase Transitions: Sublimation and Deposition


![Solid-phase Synthesis of [4.4] Spirocyclic Oximes](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58508.jpg&w=3840&q=50)